Global Drug and Gene Delivery Systems Market Overview
The key driver impacting the drug and gene delivery systems market is the growing demand for advanced drugs due to the increasing incidence of chronic diseases such as cancer, diabetes, cardiovascular disease, etc. For instance, The National Center for Biotechnology Information (NCBI) report presents that almost one in three adults suffers from multiple chronic conditions (MCCs). The WHO report shows that chronic disease accounts for 60% of the worldwide disease burden in 2020. Globally cancer is responsible for the second most leading cause of death, and it accounted for 9.6 million deaths in 2018. Similarly, diabetes is also one of the most prevalent diseases globally. As per the International Diabetic Federation (IDF), In 2019, over 463 million adults (20-79 years) were living with diabetes, and it is likely to reach 700 million by 2045. drug and gene delivery systems techniques are widely used to research and develop medicines, vaccines, antibiotics, and therapeutics used for treating such diseases. The escalating incidence of diseases such as diabetes and cancer has created a need for extensive research and enhancing drug discovery operations and research in the fields of biopharmaceuticals and biotechnology. Moreover, the growth in R&D investments with high demand for self-administration and home health care devices contributes to the drug and gene delivery systems market growth in the coming years.
According to Value Market Research, the global drug and gene delivery systems market size was valued at around USD 1,810.44 million in 2021 and is estimated to grow at a CAGR of about 26.33% during the forecast period 2022 to 2028.
The several advancements made in drug and gene delivery systems are estimated to augment drug and gene delivery systems needs in the forecast period. For example, technological advances such as Prodrug formulation particle engineering & particulate systems, nanoparticle technology, liposomes & hydrogels, and three-dimensional printing (3DP) to attain the sustained and controlled release of drugs. However, the high cost involved in the treatment may hamper the market in the long run. Also, the rise in drug recalls negatively impacts the market. The current industry trends, such as the rising investment by the market players to develop innovative drug delivery systems and high focus on R&D of gene delivery systems, are expected to offer new market opportunities for the key players.
The drug and gene delivery systems market is vast, with many local and global players. The drug and gene delivery systems market is extensive, with many international and regional players. The key market leaders follow several strategies to improve their market statuses, such as extending product portfolio, amalgamation, contracts, acquisitions, product upgrades to enlarge their market share across the globe. For instance, in February 2018, Becton, Dickinson, and Company had launched PAXgene. It is a circulating cell-free DNA blood collection tube for the application of pre-natal cancer testing. The important players studied in the report are Novartis AG, Amgen Inc., Oxford Biomedica PLC, Sibiono, Voyager Therapeutics Inc., Spark Therapeutics Inc. , Sangamo Therapeutics Inc, Others.
In this research report, the drug and gene delivery systems market is segmented by route of administration, vectors, methods, and region.
Analysis by Route of Administration
By route of administration, the report is categorized into oral, inhalation, transdermal, injectable, ocular, nasal, and topical. The oral segment dominates the route of the administration segment with over 25% share in 2020. It is due to the high potency and safety of biotechnology agents that are attracting biopharmaceutical companies to invest mainly in the research and development of these drugs. Moreover, pharmaceutical companies are focusing on reducing the amount of API per dose and increase the bioavailability at the site of action, thus contribute to the oral route of administration of drugs segment growth in the forecast period.
Analysis by Vector:
By vector, the report is categorized into viral and non-viral. Viral dominates the vector segment with over 90% share in 2020. It is because viral vectors allow complex procedures involved in various transfection procedures such as magnetofection, gene gun, hydrodynamic, and ultrasound at the high success rate of the gene transfer than its counterpart techniques. Moreover, more than 60% of the ongoing clinical trials on gene therapies are based on the viral vectors for transfection contributes to the increased demand for viral vectors segment in the forecast period.
Analysis by Method:
By the method, the report is categorized into in situ and ex vivo. In situ dominate the method segment with over 55% share in 2020. It is because most of the recently approved drugs act by in situ methods. Moreover, high focus on the in situ methods owing to their ease of performance contributes to the increased market demand in the forecast period.
Analysis by Region:
In the regional outlook of the global drug and gene delivery systems market, the North America region dominates globally with a 30% market share in the forecast period. It is due to the rising prevalence of chronic diseases in the area, technological advancement, and the domicile presence of significant players in the region. Moreover, the existence of well-established nanotechnology, biotechnology, and pharmaceutical industry, with massive awareness concerning advanced technologies for the treatment of chronic and genetic disease among the population of the U.S. and Canada, contribute to market growth across North America.
Market Segmentation covered in the Report:
By Route of Administration
By Therapy Area
- Infectious Diseases
- Rheumatoid Arthritis
- Genetic Disorders
- Neurological Disorders
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.